Table 3 Univariable and multivariable analyses for the risk factors of overall response and survival

Gender

female vs male

1.92(0.70–5.24);

.20

-

1.30(0.36–4.62);

.67

-

0.74(0.46–1.21);

.23

-

Patient age

 < 35 vs ≥ 35 years (median)

1.05(0.39–2.82);

.90

-

0.40(0.10–1.55);

.18

-

1.18(0.72–1.92);

.49

-

MAGIC criteria grade

I-II vs III-IV

17.18(4.67–63.16);

* < .001

20.12(4.28–94.37);

* < .001

0.18(0.04–0.73);

*.016

0.18(0.04–0.73);

*.016

0.22(0.11–0.45);

* < .001

0.26(0.13–0.52);

* < .001

GVHD risk category

standard vs high

29.06(6.57–128.35);

* < .001

-

0.15(0.03–0.58);

*.006

-

0.19(0.09–0.40);

* < .001

-

Underlying malignancy 

AML/MDS vs ALL or others

0.79(0.281–2.24);

.66

-

2.46(0.52–11.61);

.25

-

1.20(0.72–2.00);

.47

-

Graft source

PB vs BM

0.96(0.25–3.60);

.96

-

1.85(0.23–14.60);

.55

-

0.71(0.39–1.29);

.26

-

Donor source

.71

-

.43

-

.33

-

Matched sibling

0.56(0.14–2.20);

.41

0.00

.98

1.45(0.74–2.83);

.27

Unrelated donor

0.00

.99

2.72(0.59–12.72);

.20

1.56(0.71–3.41);

.26

Haplo donor

1.0

1.0

1.0

Center

Peking university vs others

1.47(0.48–4.46);

.49

-

2.61(0.33–20.66);

.36

-

0.92(0.52–1.64);

.79

-

Mini-dose MTX treatment

MTX vs control

8.90(1.96–40.41);

*.005

9.39(1.81–48.59);

*.008

0.78(0.21–2.91);

.71

-

0.46(0.27–0.76);

* .002

0.49(0.30–0.82);

*.007